In a significant advancement for molecular pathology, Indica Labs has launched Lung Macrodissect AI, a novel tool designed to streamline slide macrodissection workflows. The announcement marks a pivotal step in integrating artificial intelligence with digital pathology.
Takara Bio has unveiled a novel enzyme designed to enhance the safety and efficiency of mRNA production for therapeutic applications. The PrimeCap™ T7 RNA Polymerase (low dsRNA) addresses two significant challenges in mRNA synthesis: reducing immunogenic double-stranded RNA (dsRNA) and lowering the cost of capping.
Gyros Protein Technologies AB has introduced a new kit designed to streamline the detection of pre-existing antibodies against adeno-associated virus (AAV) vectors. The Gyrolab Generic Anti-Adeno Associated Virus (AAV) Kit aims to facilitate qualitative assessment of binding antibodies in both pre-clinical and clinical settings, supporting the development of AAV-based gene therapies.
Indica Labs, a global leader in AI-powered digital pathology solutions, has announced a significant update to its life sciences software suite. The 4.0 versions of HALO®, HALO AI, and HALO Link offer enhanced capabilities for researchers and pathologists, with a focus on leveraging advanced AI-powered image analysis in an open digital pathology ecosystem.
Thermo Fisher Scientific has introduced a groundbreaking solution for more precise blood genotyping in clinical research. The Applied Biosystems™ Axiom™ BloodGenomiX™ Array and Software offers a single, high-throughput assay capable of detecting most extended and rare blood groups, as well as tissue (HLA) and platelet (HPA) types.
DiaSorin has announced that its LIAISON PLEX® Yeast Blood Culture (BCY) Assay has received 510(k) clearance from the US Food and Drug Administration (FDA). This marks the second molecular multiplexing panel to be cleared for the company’s LIAISON PLEX® system, following the clearance of the Respiratory Flex Assay in March 2024.
Siemens Healthineers has announced the CE marking of its Neurofilament Light Chain (NfL) assay for multiple sclerosis (MS) management. Developed in collaboration with Novartis Pharma AG, this blood test is designed for use on the Atellica IM Analyzer and the ADVIA Centaur XP/XPT Systems.
Bio-Rad Laboratories has expanded its portfolio of molecular quality controls with the introduction of Exact Diagnostics GBS Positive and Negative Run Controls. These new products complement the previously launched Exact Diagnostics GBS Verification & Validation Panel, offering clinical laboratories a comprehensive solution for Group B Streptococcus (GBS) molecular assay quality management.
The UNIQO 160, an advanced automation system for indirect immunofluorescence assays (IFA), now incorporates AI-based evaluation of results. This innovation enables complete walkaway automation from primary sample to result proposal, significantly enhancing efficiency and standardisation in IFA analysis.
Syntegon subsidiary Pharmatec recently launched its new Modular Bioprocessing Platform (MBP), designed to address key challenges in biopharmaceutical production. The highly flexible, fully integrated and automated solution was developed for biologic drug substances, with configurations available for a range of microbial and mammalian cell culture applications.
March 2026
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.